Inside J&J’s Lab to Create a Simpler Robotic Surgery Device

Summary

Bloomberg takes an inside look at Johnson & Johnson's newly FDA-approved robotic surgery system, Ottava, and its bid to compete against established players like Intuitive Surgical. J&J executives argue Ottava's integrated table design is a differentiated innovation in a market with only 8% penetration. The company expects the platform to become financially material by the end of the decade, with additional procedure approvals and international expansion planned.

• Johnson & Johnson received FDA approval for its Ottava robotic surgery device after years of development and delays.
• Ottava integrates robotic arms into the surgical table, a design J&J says reduces OR friction and space constraints.
• The robotic surgery market is dominated by Intuitive Surgical's da Vinci, with an estimated 80% share in 2024.
• J&J executives see the market as early-stage with only 8% penetration globally and fast adoption.
• The company plans to submit for additional procedure approvals (e.g., inguinal hernia) and expand into Japan and Europe.
• J&J expects Ottava to become a material contributor to financial results toward the end of the decade.
• A surgeon interviewed notes that robotic systems do not operate autonomously and require proper patient selection and training.